Menarini secures European rights to Chinese GLP-1 obesity drug

Menarini Group, a large family‑owned pharmaceutical company in Italy, has obtained the European commercial rights to a GLP‑1 agonist developed by China’s Gan & Lee.

The agreement gives Menarini a foothold in the fast‑growing obesity and weight‑loss market, where GLP‑1 drugs have become a dominant therapeutic class.

By partnering with Gan & Lee, Menarini expands its product portfolio and aims to compete with established GLP‑1 manufacturers across Europe.

Details on pricing, launch timelines, or regulatory submissions were not disclosed in the announcement.